HIF-2α inhibitor (specialist)
Belzutifan
Brand names: Welireg
Adult dose
Dose: 120mg PO OD
Route: Oral
Frequency: OD
Clinical pearls
- VHL disease-associated tumours; advanced renal cell carcinoma
- NICE TA evaluation; ESMO RCC
- Specialist oncology — anaemia management essential
Contraindications
- Pregnancy
- Severe hepatic impairment
- Hypersensitivity
Side effects
- Anaemia (very common, often severe)
- Hypoxia
- Fatigue
- Nausea
- Headache
Interactions
- Strong CYP3A4 inhibitors/inducers
- UGT2B17 / CYP2C19 substrates
Monitoring
- Hb (baseline weekly initially)
- SpO₂
- LFTs
- Disease response
Reference: BNF; NICE TA evaluation; ESMO RCC; SmPC; https://bnf.nice.org.uk/drugs/belzutifan-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia